Caraco Pharmaceutical Laboratories Ltd
Caraco Pharmaceutical Laboratories — Shareholder Meeting (September 2008)
27 slides from Caraco Pharmaceutical Laboratories's shareholder meeting presentation, Sep 8, 2008
Slide 1: Annual Meeting
Annual Meeting September 8, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause
Slide 3: Contents
Contents I. Industry Overview II. Caraco Overview III. Fiscal 2008 in Review IV. Fiscal 2009 Initiatives & Drivers V. Summary
Slide 4: Contents
Contents I. Industry Overview II. Caraco Overview III. Fiscal 2008 in Review IV. Fiscal 2009 Initiatives & Drivers V. Summary
Slide 5: Generic Pharmaceutical Industry Overview
Generic Pharmaceutical Industry Overview The Generic Pharmaceutical Industry primarily consists of generic versions of brand pharmaceuticals that have lost their patent exclusivity or are products that do not infringe the innovator’s patent U.S. brand pharmaceutical sales for 2007 were $228 billion.
Slide 6: Contents
Contents I. Industry Overview II. Caraco Overview III. Fiscal 2008 in Review IV. Fiscal 2009 Initiatives & Drivers V. Summary
Slide 7: Company Overview
Company Overview Established in 1984, based in Detroit, MI Caraco develops, manufactures, markets and distributes generic and private-label pharmaceuticals In 1997, Sun Pharmaceutical Industries, Ltd. invested $7.5 million in Caraco through a stock purchase agreement In 2002, Caraco signed an agreem
Slide 8: Sun Pharmaceutical Industries, Ltd.
Sun Pharmaceutical Industries, Ltd. Established in 1983, Sun is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. I
Slide 9: Our Competitive Advantages
Our Competitive Advantages Size of our Product Portfolio vs. the Size of Company Ability to service our customers’ immediate needs Management Experienced in the industry Disciplined Product Portfolio Deep pipeline through diverse paths of development Many products vertically integrated via Sun API’s
Slide 10: Contents
Contents I. Industry Overview II. Caraco Overview III. Fiscal 2008 in Review IV. Fiscal 2009 Initiatives & Drivers V. Summary
Slide 11: Fiscal 2008 Financial Overview
Fiscal 2008 Financial Overview Sales of $350 million compared to $117 million over the same period last year Gross Profit of $85 million compared to $58 million over the same period last year Pre-tax Income of $42 million compared to $27 million in the previous year Cash Flow From Operations of $28
Slide 12: Fiscal 2008 in Review
Fiscal 2008 in Review 7th consecutive year of growth in sales Maintained gross profit of 49% for manufactured products SG&A as a percentage of net sales declined to 4% for Fiscal 2007, as compared to 8% for the corresponding period of Fiscal 2007. Peer group SG&A as a percentage of net sales is esti
Slide 13: Annual Results (in US $ millions)
Annual Results (in US $ millions) *Change in Fiscal year. Covers transition period from 1/1/2005 to 3/31/2005 (0) -4 -10 (25) 2004 F2005* F2006 F2007 F2008 Net Sales Gross Profit Net Income Cash Flow from operations
Slide 14: Product Market Share Trends
Product Market Share Trends Caraco’s current product portfolio consists of 54 products in 118 strengths 23 of the 54 products are in the top three of generic market share
Slide 15: Net Sales by Trade Class
Net Sales by Trade Class Fiscal 2008 19% 17% 15% 16% 33% Fiscal 2007 12% 22% 30% 16% 20% CHAIN DISTRIBUTOR GOVERNMENT MANAGED CARE/MAIL ORDER WHOLESALER
Slide 16: Internal Product Development
Internal Product Development Product Filings Fiscal 2008: Filed 8 ANDAs (7 Products) with the FDA Fiscal 2009 Q1: Filed one NDA Approvals Fiscal 2008: FDA approval of 12 ANDA’s relating to 11 products Fiscal 2009 Q1: FDA approval of 8 ANDA’s relating to 3 products
Slide 17: Internal Product Development
Internal Product Development Number of ANDA Filings Products Filed ANDAs Awaiting Approval Products Awaiting Approval
Slide 18: Product Litigation
Product Litigation Lexapro - Forest has two U.S. patents listed with the FDA that they claim cover Lexapro, the ‘712 patent and the ‘941 patent. We filed an ANDA in which we certified to the noninfringement and/or invalidity of both patents. On July 10, 2006, Forest sued us on the ‘712 patent in fed
Slide 19: Capacity
Capacity At the start of 2007, facilities included 114,000 sq ft owned and 67,000 sq ft leased for total footprint of approximately 180,000 sq ft 2008 additions Acquired and opened 135,000 sq ft distribution warehouse Expansion of 140,000 sq ft to be occupied approximately November 1, 2008 using red
Slide 20: Contents
Contents I. Industry Overview II. Caraco Overview III. Fiscal 2008 in Review IV. Fiscal 2009 Initiatives & Drivers V. Summary
Slide 21: Initiatives Fiscal 2009
Initiatives Fiscal 2009 Quality Continue to focus and improve on FDA compliance. Increase cGMP training to accommodate growing staff and compliance. Management Increase focus on succession planning. Increase management training and development.
Slide 22: Initiatives Fiscal 2009
Initiatives Fiscal 2009 Research & Development Increase research and development activities, with a view to increase the number of ANDA filings. Research possible development of brands for existing stream of products where such potential exists. Sales Increased market share for certain existing prod
Slide 23: Initiatives Fiscal 2009
Initiatives Fiscal 2009 Capacity and Efficiency Continue to invest in equipment and facilities to expand capacity to meet requirements of projected short and long-term growth while improving quality. Build or lease new facilities to meet the increased demand for production and warehousing in short a
Slide 24: Initiatives Fiscal 2009
Initiatives Fiscal 2009 Business Opportunities Increase revenue and cash by marketing ANDAs owned by Sun Pharma and other third parties. Expand our relationships with financial institutions to fortify our credit position and borrowings if necessary. Look for potential acquisitions that either comple
Slide 25: Drivers Fiscal 2009
Drivers Fiscal 2009 FDA product approvals Maximize market share on current portfolio Improve operational execution Streamline processes and reduce operational costs
Slide 26: Contents
Contents I. Industry Overview II. Caraco Overview III. Fiscal 2008 in Review IV. Fiscal 2009 Initiatives & Drivers V. Summary
Slide 27: Summary
Summary We are Built to Fit the Current Competitive Environment Size and management structure conducive to success Large basket of products awaiting FDA approval Vertical integration with Sun allows us to enjoy longer lifecycles and value on products that we market Increasing capacity Focus on Quali
Caraco Pharmaceutical Laboratories — Shareholder Meeting (September 2008) on 6ix